AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase 1b/2a Study
Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35.030 is a clinical stage vaccine generated with the proprietary SupraAntigen™ platform addressing proteinopathies across …